COVID 19 is the #5 most commonly reported adverse reaction for HUMAN IMMUNOGLOBULIN G, manufactured by ADMA Biologics, Inc.. There are 2,125 FDA adverse event reports linking HUMAN IMMUNOGLOBULIN G to COVID 19. This represents approximately 2.9% of all 73,013 adverse event reports for this drug.
Patients taking HUMAN IMMUNOGLOBULIN G who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COVID 192,125 of 73,013 reports
COVID 19 is a less commonly reported adverse event for HUMAN IMMUNOGLOBULIN G, but still significant enough to appear in the safety profile.
Other Side Effects of HUMAN IMMUNOGLOBULIN G
In addition to covid 19, the following adverse reactions have been reported for HUMAN IMMUNOGLOBULIN G:
COVID 19 has been reported as an adverse event in 2,125 FDA reports for HUMAN IMMUNOGLOBULIN G. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COVID 19 with HUMAN IMMUNOGLOBULIN G?
COVID 19 accounts for approximately 2.9% of all adverse event reports for HUMAN IMMUNOGLOBULIN G, making it a notable side effect.
What should I do if I experience COVID 19 while taking HUMAN IMMUNOGLOBULIN G?
If you experience covid 19 while taking HUMAN IMMUNOGLOBULIN G, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.